Clinical Trial Update: Zibotentan Better Renal Scleroderma Outcome Study [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Zibotentan for renal outcomes in systemic sclerosis (scleroderma) has completed, with results summarized in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Systemic Sclerosis
• Systemic Sclerosis Renal Crisis

Drugs mentioned

• Zibotentan (zibotentan)

Snippet

Sponsor: University College, London | Conditions: Scleroderma, Scleroderma Renal Crisis | Phase 2 | Status: COMPLETED